Evidence map›Paper›PMID 34947512›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Camptothecin Encapsulated in β-Cyclodextrin-EDTA-Fe

Aisha Farhana, Avin Ee-Hwan Koh, Pooi Ling Mok, Abdullah Alsrhani, Yusuf Saleem Khan, Suresh Kumar Subbiah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Aisha FarhanaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0002-4631-2769
Avin Ee-Hwan KohDepartment of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Malaysia.
Pooi Ling MokDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0001-9688-0716
Abdullah AlsrhaniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0002-6839-8866
Yusuf Saleem KhanDepartment of Anatomy, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0001-8765-1428
Suresh Kumar SubbiahDepartment of Medical Microbiology and Parasitology, Universiti Putra Malaysia (UPM), Serdang 43400, Malaysia.ORCID 0000-0002-0505-7554
Jouf University · SAUniversiti Putra Malaysia · MY

Funding

Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia 375213500
6 · The paper itself

Abstract

Cancer progresses through a distinctive reprogramming of metabolic pathways directed by genetic and epigenetic modifications. The hardwired changes induced by genetic mutations are resilient, while epigenetic modifications are softwired and more vulnerable to therapeutic intervention. Colon cancer is no different. This gives us the need to explore the mechanism as an attractive therapeutic target to combat colon cancer cells. We have previously established the enhanced therapeutic efficacy of a newly formulated camptothecin encapsulated in β-cyclodextrin-EDTA-Fe

Indexed as

colon cancerepigenetic modulationmetabolic reprogrammingnanoparticlestranscriptome analysis

Identifiers

PMID34947512
PMCPMC8705212
OpenAlexW3214752980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.